Level B· Emerging clinical evidence with positive signalsRandomized Controlled TrialEurope PMCOpen access

Advancing mesenchymal stem cell therapy for kidney diseases in companion animals: from mechanisms to clinical application

Yu Y., Wang Y., Mu Y., Wang S., Zhang X., Song Y.

Randomized Controlled Trial on Chronic Kidney Disease, Immune Modulation, published in Front Vet Sci (2026) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Randomized Controlled Trial
Journal
Front Vet Sci (2026)
Reported sample size
—
Source database
Europe PMC
PMID
41971026
PMCID
PMC13067890
DOI
10.3389/fvets.2026.1771337

Abstract (original English)

Acute and chronic kidney diseases are major clinical challenges in companion animals, yet therapeutic options for reversing established injury remain limited. Mesenchymal stem cells (MSCs) have emerged as a promising therapy due to their immunomodulatory and tissue-repair properties. This review synthesizes current evidence on MSC therapy for kidney disease in cats and dogs, with a focus on mechanisms, preconditioning strategies, delivery routes, and clinical outcomes. Key findings indicate that MSCs exert renoprotective effects primarily through paracrine-mediated immunomodulation rather than direct differentiation. Intravenous administration, while simple, results in >80% pulmonary entrapment and renal homing below 5%; arterial or local injection increases homing to 15-20% but carries procedural risks and lacks standardized dosing. Preconditioning strategies (hypoxia, melatonin, ATRA) enhance MSC survival and homing in rodent models, but feline- and canine-specific validation remains limited. Clinical data from 19 studies in cats/dogs demonstrate that MSC therapy is generally safe, with most adverse events being infusion-related and transient. In feline CKD, consistent trends toward improved glomerular filtration rate and quality of life are reported, although statistical significance is rarely achieved. In canine AKI, MSC therapy improves survival and renal function, but res

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research